BidaskClub upgraded shares of Zai Lab (NASDAQ:ZLAB) from a sell rating to a hold rating in a research report sent to investors on Thursday.
Separately, Zacks Investment Research upgraded Zai Lab from a hold rating to a buy rating and set a $27.00 target price on the stock in a research note on Wednesday, August 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of Hold and an average target price of $34.00.
ZLAB stock traded down $0.70 on Thursday, hitting $17.16. 2,331 shares of the company’s stock were exchanged, compared to its average volume of 124,998. Zai Lab has a 12-month low of $14.29 and a 12-month high of $28.43. The company has a market cap of $1.00 billion, a price-to-earnings ratio of -7.40 and a beta of 2.70.
About Zai Lab
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
See Also: What are the Benefits of Index Funds?
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.